TIAA CREF Investment Management LLC raised its position in Jounce Therapeutics, Inc. (NASDAQ:JNCE) by 519.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,532 shares of the company’s stock after purchasing an additional 54,119 shares during the quarter. TIAA CREF Investment Management LLC owned approximately 0.20% of Jounce Therapeutics worth $905,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Teachers Advisors LLC grew its stake in Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock valued at $158,000 after purchasing an additional 2,347 shares in the last quarter. Alliancebernstein L.P. purchased a new position in Jounce Therapeutics in the second quarter valued at about $177,000. Swiss National Bank purchased a new position in Jounce Therapeutics in the second quarter valued at about $188,000. Paloma Partners Management Co purchased a new position in Jounce Therapeutics in the first quarter valued at about $212,000. Finally, Goldman Sachs Group Inc. purchased a new position in Jounce Therapeutics in the first quarter valued at about $271,000. Hedge funds and other institutional investors own 44.34% of the company’s stock.
A number of research analysts have commented on JNCE shares. Zacks Investment Research upgraded Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Friday, August 11th. Robert W. Baird restated a “buy” rating and issued a $30.00 target price on shares of Jounce Therapeutics in a research note on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.67.
Jounce Therapeutics, Inc. (JNCE) opened at $14.77 on Friday. Jounce Therapeutics, Inc. has a 52 week low of $11.05 and a 52 week high of $29.29.
Jounce Therapeutics (NASDAQ:JNCE) last issued its earnings results on Wednesday, August 9th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. The firm had revenue of $20.29 million during the quarter, compared to analysts’ expectations of $19.94 million. During the same quarter last year, the firm earned ($7.23) EPS. analysts expect that Jounce Therapeutics, Inc. will post -0.73 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “TIAA CREF Investment Management LLC Purchases 54,119 Shares of Jounce Therapeutics, Inc. (JNCE)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/12/tiaa-cref-investment-management-llc-purchases-54119-shares-of-jounce-therapeutics-inc-jnce.html.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Want to see what other hedge funds are holding JNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jounce Therapeutics, Inc. (NASDAQ:JNCE).
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.